Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap
Copyright © 2022 Elsevier Inc. All rights reserved..
The term asthma-chronic obstructive pulmonary disease (COPD) overlap applies where there are features of asthma and COPD. Agents targeting eosinophilic inflammation have transformed asthma management and indicate promise across airways disease, whereas agents targeting neutrophilic inflammation have demonstrated limited efficacy. Successful treatment of airway dysbiosis, mucous hypersecretion, or airway remodeling may occur with better understanding of the impact of current agents on specific clinical end points or through novel approaches. Biomarkers indicating specific disease mechanisms are key to select appropriate populations for clinical trials and identify subgroups likely to benefit from targeted treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Immunology and allergy clinics of North America - 42(2022), 3 vom: 01. Aug., Seite 671-690 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diver, Sarah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACO |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 10.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.iac.2022.04.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344837831 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344837831 | ||
| 003 | DE-627 | ||
| 005 | 20231226023706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.iac.2022.04.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344837831 | ||
| 035 | |a (NLM)35965053 | ||
| 035 | |a (PII)S0889-8561(22)00027-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diver, Sarah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 10.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a The term asthma-chronic obstructive pulmonary disease (COPD) overlap applies where there are features of asthma and COPD. Agents targeting eosinophilic inflammation have transformed asthma management and indicate promise across airways disease, whereas agents targeting neutrophilic inflammation have demonstrated limited efficacy. Successful treatment of airway dysbiosis, mucous hypersecretion, or airway remodeling may occur with better understanding of the impact of current agents on specific clinical end points or through novel approaches. Biomarkers indicating specific disease mechanisms are key to select appropriate populations for clinical trials and identify subgroups likely to benefit from targeted treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACO | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a Dysbiosis | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Mucus | |
| 650 | 4 | |a Remodeling | |
| 650 | 4 | |a Therapies | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Brightling, Chris E |e verfasserin |4 aut | |
| 700 | 1 | |a Greening, Neil J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology and allergy clinics of North America |d 1990 |g 42(2022), 3 vom: 01. Aug., Seite 671-690 |w (DE-627)NLM087751623 |x 1557-8607 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:3 |g day:01 |g month:08 |g pages:671-690 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.iac.2022.04.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 3 |b 01 |c 08 |h 671-690 | ||